



Paper Ref
 4.2

Meeting Title Trust Board (held in Public)	Meeting Date 2 February 2023
Reporting Committee	Quality Committee
Committee Chaired By	Anne Cooper: Non-Executive Director
Lead Executive Director	Clare Ashby: Interim Executive Director of Executive Director of Quality, Governance and Performance Assurance
Date of Last Committee Meeting[s]	24 November 2022 and 8 December 2023

Summary of Key Matters Considered and Decisions Taken

The Committee has held two meetings since its last report to the Board in November 2022. The meetings were held via videoconference, and both were quorate.

The key areas of discussion during the meetings are noted below.

24 November 2022

- The Committee was updated on work being undertaken around diversity and Inclusion, sickness absence and recruitment.
- An update was provided about the changes to the National Patient Safety Framework and impact for the Trust. A business case had been developed to recruit a domestic abuse specialist within the Safeguarding team.
- The Committee noted the impact on outcomes due to operational pressures and the triangulation across Category 1 and Category 2 incidents. The increase in clinical incidents related to drug errors was noted. The Committee requested an update be provided on pre-packed prescription only medicines.
- The Committee received and approved the Resuscitation Plan, noting that several business cases would be required to deliver the plan, which would be incorporated into the 2023-24 Business Plan.
- A deep dive session was held covering Absence Management.

8 December 2022

- The Committee received routine assurance reports in relation to Clinical Development and innovation, Quality Improvement, Transformation programme, significant events and lessons learned, and Freedom to speak up. Note was made of the rise in serious incidents and patient complaints and the impact this had on the respective teams, as well as patients/relatives involved.
- The Committee reviewed the Corporate Risks Register and Board Assurance Framework as relevant to the responsibilities of the Committee. Discussions were held around the way the Trust managed risks and opportunities to refine this further. Of particular note was the emerging risk related to Industrial Action and the continued high risk related to hospital handover delays. An additional area of escalating risk was related to the Aadastra system in IUC/111.



Risks Identified / Matters of Concern and Mitigating Actions

During the meeting on 24 November, attention had been drawn to the areas of the Board Assurance Framework. It was also noted that those risks identified were included within the Corporate Risk Register. No new risks were identified at the meeting on 8 December, and any risks arising had been discussed and considered during the meeting.

Matters requiring Board level consideration and/or approval

At its meeting on 24 November 2022, the Committee agreed to escalate to the Trust Board:

- Staffing levels to support serious incidents and complaints case load.
- Impact on outcomes due to pressures across all three service lines, specifically the impact on Category 1 and Category 2 incidents.

At its meeting on 8 December 2022, the Committee agreed to escalate to the Trust Board:

- Concern around the number of serious incidents and complains that remain under investigation, with likely increased case rates over Winter.
- Limited resources resulting in lengthy response timescales for SI's.

Date of next Committee Meetings:	23 February 2023 and 9 March 2023
----------------------------------	-----------------------------------